These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

956 related items for PubMed ID: 31208359

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY, Im K, Park SN, Kwon J, Kim JA, Lee DS.
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ, Rashid M, Ahmed N, Nadeem M, Shamsi TS.
    Asian Pac J Cancer Prev; 2016 May; 17(3):923-6. PubMed ID: 27039813
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.
    Giraldo-Rincón AI, Naranjo Molina S, Gomez-Lopera N, Aguirre Acevedo D, Ucroz Benavidez A, Gálvez Cárdenas K, Cuellar Ambrosí F, Torres JD, Ospina S, Palacio K, Gaviria Jaramillo L, Muñeton CM, Vasquez Palacio G.
    Colomb Med (Cali); 2023 May; 54(3):e2035353. PubMed ID: 38111518
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Molecular genetic evaluation of myeloproliferative neoplasms.
    Azzato EM, Bagg A.
    Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [Abstract] [Full Text] [Related]

  • 17. Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).
    Zulkeflee RH, Zulkafli Z, Johan MF, Husin A, Islam MA, Hassan R.
    Int J Environ Res Public Health; 2021 Jul 16; 18(14):. PubMed ID: 34300032
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations.
    Okabe M, Yamaguchi H, Usuki K, Kobayashi Y, Kawata E, Kuroda J, Kimura S, Tajika K, Gomi S, Arima N, Mori S, Ito S, Koizumi M, Ito Y, Wakita S, Arai K, Kitano T, Kosaka F, Dan K, Inokuchi K.
    Leuk Res; 2016 Jan 16; 40():68-76. PubMed ID: 26614694
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.